MedPath

Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications

Withdrawn
Conditions
Cancer of the Esophagus
Interventions
Device: Nasal High flow Oxygen
Registration Number
NCT04272268
Lead Sponsor
University Hospitals of North Midlands NHS Trust
Brief Summary

The use of nasal high flow in patients undergoing oesophagectomy is a novel technique that has not been previously studied.

Nasal high flow will be delivered postoperatively to patients undergoing oesophagectomy in a tertiary cancer referral centre. This single-centre cohort study will evaluate the safety of using nasal high flow in oesophagectomy patients. Physiological parameters, adverse events and clinical outcome will be recorded in consecutive patients undergoing oesophagogastric surgery.

This study will challenge the hypothesis that the use of nasal high-flow will lower the rates of breathing complications such as pneumonia thereby reducing the demands on intensive care, shortening hospital stay and improving patient quality of life. The results will inform the design of a larger multicentre clinical trial comparing nasal high flow to conventional methods by facilitating sample size calculation.

Detailed Description

Respiratory complications including pneumonia, pleural effusion, adult respiratory distress syndrome and pulmonary embolism will be recorded. The primary endpoint will be the rate of postoperative respiratory complications within 30 days of oesophagectomy. Technical complications related to nasal high flow administration will be recorded and reasons for discontinuing nasal high flow documented. Other outcome including mortality, hospital stay, surgical complications and respiratory complications within 90 days of surgery will be considered as secondary endpoints. These data will assess the feasibility and safety of using nasal high flow in patients undergoing oesophagectomy. The rate of respiratory complications will be determined in a cohort of consecutive surgical patients together with other measures of outcome to form the basis of a series worthy of reporting. This may help gain insight into whether using nasal high flow could benefit patients, and whether further research to compare nasal high flow to conventional respiratory support would be of value.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Over 18 years old
  • Undergoing Ivor-Lewis (2-stage) oesophagectomy
  • Successfully extubated within 4 hours after surgery
Exclusion Criteria
  • History of bullous emphysematous disease
  • Lack of capacity to consent
  • Significant air leak during surgery
  • Incurable disease found at surgery leading to no surgical resection
  • Failure of extubation and spontaneous breathing within 4 hours after surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Nasal High flow OxygenNasal High flow OxygenFollowing consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
Primary Outcome Measures
NameTimeMethod
Rate of respiratory complications within 30 days after surgery30 days

including pneumonia, pleural effusion, adult respiratory distress syndrome and pulmonary embolism.

Secondary Outcome Measures
NameTimeMethod
90 day mortality90 days
Recruitment rate90 days

To facilitate sample size calculation for such a randomized controlled trial.

30 day mortality30 days
The proportion of blood gases performed on time5 days
The proportion of missing results5 days
90 day respiratory complication rate90 days

Trial Locations

Locations (1)

Robert James Bowler

🇬🇧

Stoke-on-Trent, Staffordshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath